CAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

A securities class action alleges Capricor Therapeutics failed to disclose that it changed the pre-specified statistical analysis plan for its Phase 3 HOPE-3 trial without FDA agreement, leaving results the agency characterized as "post-hoc and exploratory." NEW YORK, Aug. 26, 2026...